When the American Cancer Society (ACS) last updated its guidance in 2010, two large trials had reached conflicting conclusions about whether prostate-specific antigen (PSA) testing, the primary tool used to screen for prostate cancer before symptoms appear, saved lives. The group stopped short of recommending PSA testing, and instead encouraged men to make the decision themselves after talking through the pros and cons of a PSA test with their doctor.